Complement C4d Antikörper

Produktnummer ABIN3026817

Produktdetails anti-Complement C4d Antikörper

Target: Complement C4d (C4d) (Complement Component C4d (C4d))

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser Complement C4d Antikörper ist unkonjugiert

Applikation: Immunofluorescence (IF), ELISA, Immunohistochemistry (Paraffin-embedded Sections) (IHC (p))

Produktmerkmale: This mAb is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound C4d. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of Abs to specific target molecules. Following activation and degradation of the C4 Molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment.

Aufreinigung: Protein G affinity chromatography

Immunogen: Recombinant human C4d protein was used as the immunogen for this Complement 4d antibody.

Klon: SPM545

Isotyp: IgG1 kappa

Anwendungsinformationen

Applikationshinweise: The optimal dilution of the Complement 4d antibody for each application should be determined by the researcher.

1. Staining of formalin-fixed tissues requires boiling tissue sections in 10  mM Tris with 1  mM EDTA,  pH 9.0, for 10-20 min followed by cooling at RT for 20 minutes.
2. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.\. ELISA: 1-2 μg/mL (order BSA/azide free format),Immunofluorescence: 1-2 μg/mL,Immunohistochemistry (FFPE): 0.5-1 μg/mL for 30 minutes at RT (1),Prediluted format: incubate for 30 min at RT (2)

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Konzentration: 1 mg/mL

Buffer: 1 mg/mL in 1X PBS, BSA free, sodium azide free

Konservierungsmittel: Azide free

Lagerung: 4 °C,-20 °C

Informationen zur Lagerung: Store the Complement 4d antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).

Details zu Complement C4d

Target: Complement C4d (C4d) (Complement Component C4d (C4d))

Andere Bezeichnung: Complement 4d (C4d Produkte)

Hintergrund: This mAb is specific to Complement 4d (C4d) and it reacts with the secreted as well as cell-bound C4d. C4d is a degradation product of the activated complement factor C4b. Complement 4b is typically activated by binding of Abs to specific target molecules. Following activation and degradation of the C4 Molecule, thio-ester groups are exposed, which allow transient, covalent binding of the degradation product Complement 4d to endothelial cell surfaces and extracellular matrix components of vascular basement membranes near the sites of C4 activation. The presence of C4d in peritubular capillaries is a key indicator for acute humoral (i.e. antibody-mediated) rejection of kidney, heart, pancreas and lung allografts. As an established marker of antibody-mediated acute renal allograft rejection and its proclivity for endothelium, this component can be detected in peritubular capillaries in chronic renal allograft rejection as well as hyperacute rejection, acute vascular rejection, acute cellular rejection, and borderline rejection. It has been shown to be a significant predictor of transplant kidney graft survival. Anti-C4d, combined with anti-C3d, can be utilized as a tool for diagnosis of allograft rejection that may warrant a prompt and aggressive anti-rejection treatment.